CLX / The Clorox Company - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2025 OR ☐ Transition report pursuant to Sectio

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2025 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except per share data) Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of ma

Reconciliation of Economic Profit (Unaudited).

Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY25 FY24 FY23 Earnings before income taxes $ 1,078 $ 398 $ 238 Add back: Certain U.S. GAAP items (2) 159 580 605 Interest expense 88 90 90 Earnings before income taxes, certain U.S. GAAP items and interest expense 1,325 1,068 933 Less: Income taxes on earnings before income taxes, certain U.S. GA

xcess Long-Term Disability

Exhibit 10.32 THE CLOROX COMPANY EXCESS LONG-TERM DISABILITY PLAN (As Amended and Restated Effective as of January 1, 2005) TABLE OF CONTENTS Page SECTION 2. ELIGIBILITY AND COMMENCEMENT OF PARTICIPATION 1 (a) Eligibility 1 (b) Enrollment and Commencement of Coverage 1 (c) Suspension 1 (d) Continued Participation During Leave of Absence 2 (e) Termination of Participation 2 SECTION 3. ELIGIBILITY F

Brita GP, LLC

Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Iodine Holdings, Inc.

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended Jun. 30, 2025 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness 14% 18% —% —% (4)% 14% 18% Household 7 13 — — (6) 7 13 Lifestyle 3 8 — — (5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Em

Fiscal year 2025

PRESS RELEASE Clorox Reports Q4 and FY25 Results, Provides FY26 Outlook Delivers strong margin expansion and adjusted EPS growth for FY25 despite challenging environment in the second half of the fiscal year OAKLAND, California, July 31, 2025 — The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2025, which ended June 30, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

Conflict Minerals Report of The Clorox Company

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2024 This Conflict Minerals Report (this “Report”) of The Clorox Company (the “Company” or “Clorox”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2024 to December 31, 2024. Rule 13p-1 requires

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-0595760 (I.R.S. Employer Identification No.) 1221 Broadway, Oakland, California 94612-1888 (Address of principal executive o

Amended and Restated Bylaws

Exhibit 3.2 THE CLOROX COMPANY AMENDED AND RESTATED BYLAWS (as of May 19, 2025) ARTICLE I STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as the Bo

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025   THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-0595

Clorox Announces Election of Gina Boswell to its Board of Directors

Exhibit 99.1 PRESS RELEASE Clorox Announces Election of Gina Boswell to its Board of Directors OAKLAND, Calif., May 12, 2025 — The Clorox Company (NYSE: CLX) today announced the election of Gina Boswell to its board of directors, effective May 19, 2025. Boswell, 62, is the chief executive officer of Bath & Body Works, Inc., and also serves on its board. Her extensive leadership and operational exp

Full year 2025 outlook (estimated range)

PRESS RELEASE Clorox Reports Q3 Fiscal Year 2025 Results, Updates Outlook Delivers lower-than-expected sales amid a challenging and volatile consumer and geopolitical environment while maintaining overall market shares and delivering its 10th consecutive quarter of gross margin expansion OAKLAND, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLOROX

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended Mar. 31, 2025 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness 3% 7% —% —% (4)% 3% 7% Household (11) (9) — — (2) (11) (9) Lifestyle (3) (2

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Empl

Credit Agreement, dated as of March 25, 2025, among The Clorox Company, the lenders listed therein, JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as Administrative Agents, and JPMorgan Chase Bank, N.A., as Servicing Agent.

Exhibit 10.1 EXECUTION VERSION $1,200,000,000 CREDIT AGREEMENT dated as of March 25, 2025 among The Clorox Company, The Banks Listed Herein, JPMorgan Chase Bank, N.A., Citibank, N.A. and Wells Fargo Bank, National Association, as Administrative Agents, JPMorgan Chase Bank, N.A., as Servicing Agent, Royal Bank of Canada, The Bank of Nova Scotia and U.S. Bank National Association, as Documentation A

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-05

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Three months ended Dec. 31, 2024

The Clorox Company Three months ended Dec. 31, 2024 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness (13)% (11)% —% —% (2)% (13)% (11)% Household (11) (11) — — — (11) (11) Life

Three months ended Dec. 31, 2024

PRESS RELEASE Clorox Reports Q2 Fiscal Year 2025 Results, Updates Outlook OAKLAND, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLO

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Clorox CFO Kevin Jacobsen to Retire; Luc Bellet Named CFO

Exhibit 99.1 PRESS RELEASE Clorox CFO Kevin Jacobsen to Retire; Luc Bellet Named CFO OAKLAND, California, Jan. 28, 2025 — The Clorox Company (NYSE: CLX) today announced that after nearly 30 years with the company, Chief Financial Officer Kevin Jacobsen has decided to retire effective April 1. Luc Bellet, an 18-year Clorox veteran, will succeed Kevin and they will work together on an orderly transi

Clorox Announces Election of Stephen Bratspies and Pierre Breber to its Board of Directors

Exhibit 99.1 PRESS RELEASE Clorox Announces Election of Stephen Bratspies and Pierre Breber to its Board of Directors OAKLAND, Calif., November 20, 2024 — The Clorox Company (NYSE: CLX) today announced the election of Stephen Bratspies and Pierre Breber, effective as of today, to its board of directors, adding deep leadership, operational and financial experience that aligns with Clorox’s strategi

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2024

Exhibit 10.2 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this nonqualified stock option agreement (the “A

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CL

Form of Restricted Stock Unit Award Agreement under the Company’s 2005 Stock Incentive Plan (Annual Grant) for awards made in 2024.

Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the

Three months ended Sep. 30, 2024

The Clorox Company Three months ended Sep. 30, 2024 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness 38% 38% —% —% —% 38% 38% Household 38 43 — — (5) 38 43 Lifestyle 40 48 — —

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2024.

Exhibit 10.1 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Agreement”), the following number of Perform

Three months ended Sep. 30, 2024

PRESS RELEASE Clorox Reports Q1 Fiscal Year 2025 Results, Updates Outlook OAKLAND, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Defin

Clorox Completes Previously Announced Divestiture of its Better Health VMS Business

Exhibit 99.1 PRESS RELEASE Clorox Completes Previously Announced Divestiture of its Better Health VMS Business OAKLAND, California, Sept. 10, 2024 — The Clorox Company (NYSE: CLX) today announced the completion of the previously disclosed divestiture of its Better Health Vitamins, Minerals and Supplements (VMS) business in its entirety to an affiliate of Piping Rock Health Products, LLC. The dives

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.

The Clorox Company Policy Regarding Clawback of Incentive Compensation, amended and restated, effective October 2, 2023.

THE CLOROX COMPANY POLICY REGARDING CLAWBACK OF INCENTIVE COMPENSATION As Amended and Restated Approval Date: November 14, 2023 Effective Date: October 2, 2023 The Management Development and Compensation Committee of the Board of Directors of The Clorox Company (the “Committee”) has determined that it is in the best interest of The Clorox Company (“CLX”) and its shareholders to implement this Policy Regarding Clawback of Incentive Compensation, as it may be amended from time to time (this “Clawback Policy”, which shall constitute the Restatement Clawback Policy in Part A and the Detrimental Conduct Policy in Part B).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________ ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2024 OR ☐ Transition report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Reconciliation of Economic Profit (Unaudited).

Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY24 FY23 FY22 Earnings before income taxes $ 398 $ 238 $ 607 Add back: Certain U.S. GAAP items (2) 580 605 61 Interest expense 90 90 106 Earnings before income taxes, certain U.S. GAAP items and interest expense 1,068 933 774 Less: Income taxes on earnings before income taxes, certain U.S. GAAP i

Brita GP, LLC

Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Iodine Holdings, Inc.

The Clorox Company Insider Trading Policy, effective May 20, 2024.

Corporate Policy Policy Title: Insider Trading Date Issued: 5/20/2024 Policy Category: Ethics and Standards References to “The Clorox Company”, “Clorox”, and “Company” refer to The Clorox Company and its subsidiary companies worldwide.

The Clorox Company Second Amended and Restated Executive Retirement Plan, effective May 20, 2024.

THE CLOROX COMPANY SECOND AMENDED AND RESTATED EXECUTIVE RETIREMENT PLAN (Effective May 20, 2024) ARTICLE I.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except per share data) Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of ma

Health and Wellness

PRESS RELEASE Clorox Reports Q4 and FY24 Results, Provides FY25 Outlook Company Announces Sale of its Better Health Vitamins, Minerals and Supplements Business OAKLAND, California, Aug.

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended June 30, 2024 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness —% 2% —% —% (2)% —% 2% Household (10) (5) — — (5) (10) (5) Lifestyle (2) —

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

Conflict Minerals Report of The Clorox Company

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2023 This Conflict Minerals Report (this “Report”) of The Clorox Company (the “Company” or “Clorox”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2023, to December 31, 2023. Rule 13p-1 require

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-0595760 (I.R.S. Employer Identification No.) 1221 Broadway, Oakland, California 94612-1888 (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLOROX

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended Mar. 31, 2024 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures (1) Foreign Exchange Impact Price Mix and Other (2) Organic Sales Growth/ (Decrease) (Non-GAAP) (3) Organic Volume (4) Health and Wellness (6)% (4)% —% —% (2)% (6)% (4)% Household (4) (3) — — (1) (4) (3) Lifestyle

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Total Company (1)

PRESS RELEASE Clorox Reports Q3 Fiscal Year 2024 Results, Updates Outlook OAKLAND, Calif.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-05

Clorox Divests its Operations in Argentina, Uruguay and Paraguay  Sale advances Clorox’s IGNITE strategy to evolve its portfolio for long term profitable growth

Exhibit 99.1 PRESS RELEASE Clorox Divests its Operations in Argentina, Uruguay and Paraguay  Sale advances Clorox’s IGNITE strategy to evolve its portfolio for long term profitable growth OAKLAND, Calif., March 21, 2024 — The Clorox Company (NYSE: CLX) (the “company” or “Clorox”) today announced the sale of certain wholly owned subsidiaries (collectively, “Clorox Argentina”), with operations in Ar

CLX / The Clorox Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0626-cloroxcothe.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Clorox Co/The Title of Class of Securities: Common Stock CUSIP Number: 189054109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2023.

Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this nonqualified stock option agreement (the “A

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Three months ended Dec. 31, 2023

PRESS RELEASE Clorox Reports Q2 Fiscal Year 2024 Results, Updates Outlook OAKLAND, Calif.

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2023.

Exhibit 10.2 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Agreement”), the following number of Perform

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended Dec. 31, 2023 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness 25% 22% —% —% 3% 25% 22% Household 9 4 — — 5 9 4 Lifestyle 21 24 — — (3) 21 24

Form of Restricted Stock Unit Award Agreement under the Company’s 2005 Stock Incentive Plan (Off-Cycle Grant)

Exhibit 10.5 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLO

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Annual Grant) for awards made in 2023

Exhibit 10.4 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the

The Clorox Company First Amended and Restated Executive Retirement Plan, effective November 14, 2023

THE CLOROX COMPANY FIRST AMENDED AND RESTATED EXECUTIVE RETIREMENT PLAN (Effective November 14, 2023) ARTICLE I.

CLX / The Clorox Company / STATE STREET CORP Passive Investment

SC 13G/A 1 CloroxCoThe.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING CLOROX CO/THE (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 189054109 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHIC

Clorox Board Names Linda Rendle Chair; Matthew Shattock to Become Lead Independent Director

Exhibit 99.1 Clorox Board Names Linda Rendle Chair; Matthew Shattock to Become Lead Independent Director OAKLAND, Calif., Nov.16, 2023 – The Clorox Company (NYSE: CLX) today announced that its board of directors has elected CEO Linda Rendle to the role of chair of the board of directors, effective Jan. 1, 2024, and that Matthew Shattock, Clorox’s current board chair, will become lead independent d

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31

he Clorox Company Annual Incentive Plan, amended and restated as of September 20, 2023

Exhibit 10.1 THE CLOROX COMPANY ANNUAL INCENTIVE PLAN As Amended and Restated Effective as of September 20, 2023 (the “Effective Date”) 1.Purpose. The purpose of The Clorox Company Annual Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a Delaware corporatio

Total Company (1)

PRESS RELEASE Clorox Reports Q1 Fiscal Year 2024 Results, Updates Outlook OAKLAND, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CL

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended Sept. 30, 2023 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (23)% (29)% —% —% 6% (23)% (29)% Household (23) (30) — — 7 (23) (30) Lifestyle

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted b

Important Notice Regarding the Availability of Proxy Materials for The Clorox Company’s Annual Meeting of Shareholders to be Held on November 15, 2023

+ Online Go to www.envisionreports.com/CLX or scan the QR code – login details are located in the shaded bar below. Shareholder Meeting Notice Important Notice Regarding the Availability of Proxy Materials for The Clorox Company’s Annual Meeting of Shareholders to be Held on November 15, 2023 This notice is to advise you that the proxy materials for the Annual Meeting of Shareholders are available

Notice of Annual Meeting of Shareholders

Table of Contents Letter from Our Independent Chair Clorox delivered a year of strong financial performance and meaningful progress on our integrated ESG goals to drive long-term value for our shareholders and other stakeholders, under the leadership of our CEO Linda Rendle and with the oversight of the Board.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 THE CLOROX COMPAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Three Months Ended Sept. 30, 2023 (Preliminary estimated range)

Exhibit 99.1 Clorox Provides Preliminary Q1 Financial Information and Operations Update OAKLAND, Calif., Oct. 4, 2023 — The Clorox Company (NYSE: CLX) (the “Company” or “Clorox”) today announced certain preliminary financial information for the first quarter of fiscal 2024, which ended Sept. 30, 2023, as well as an operations update following the previously announced cybersecurity attack that impa

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Reconciliation of Economic Profit (Unaudited).

Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY23 FY22 FY21 Earnings before income taxes $ 238 $ 607 $ 900 Add back: Certain U.S. GAAP charges (2) 605 61 357 Interest expense 90 106 99 Less: Saudi JV acquisition gain (2) — — (82) Earnings before income taxes, certain U.S. GAAP items and interest expense 933 774 1,274 Less: Income taxes on ea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________ ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2023 OR ☐ Transition report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2023 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except per share data) Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of ma

Clorox de Mexico, S de RL de C.V.

Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Iodine Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Health and Wellness (1)

PRESS RELEASE Clorox Reports Q4 and FY23 Results, Provides FY24 Outlook OAKLAND, California, Aug.

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three months ended June 30, 2023 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness 14% (2)% —% —% 16% 14% (2)% Household 14 (3) — — 17 14 (3) Lifestyle 14 (1) — —

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

Bylaws (amended and restated).

Exhibit 3.2 THE CLOROX COMPANY AMENDED AND RESTATED BYLAWS (as of May 22, 2023) ARTICLE I STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as the Bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31-0595760 (I.R.S. Employer Identification No.) 1221 Broadway, Oakland, California 94612-1888 (Address of principal executive o

Conflict Minerals Report of The Clorox Company

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2022 This Conflict Minerals Report (this “Report”) of The Clorox Company (the “Company” or “Clorox”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2022, to December 31, 2022. Rule 13p-1 require

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLOROX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 TH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Empl

% Change(1)

PRESS RELEASE Clorox Reports Q3 Fiscal Year 2023 Results, Updates Outlook OAKLAND, Calif.

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three Months Ended March 31, 2023 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness 7% (16)% —% —% 23% 7% (16)% Household 2 (12) — — 14 2 (12) Lifestyle 15 — — —

The Clorox Company Annual Incentive Plan, amended and restated as of

Exhibit 10.1 THE CLOROX COMPANY ANNUAL INCENTIVE PLAN As Amended and Restated Effective as of February 14, 2023 1.Purpose. The purpose of The Clorox Company Annual Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a Delaware corporation (the “Company”) and it

CLX / Clorox Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Clorox Co. Title of Class of Securities: Common Stock CUSIP Number: 189054109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLO

% Change(1)

PRESS RELEASE Clorox Reports Q2 Fiscal Year 2023 Results, Updates Outlook OAKLAND, California, Feb.

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three Months Ended December 31, 2022 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (2)% (19)% —% —% 17% (2)% (19)% Household 9 3 — — 6 9 3 Lifestyle 2 (6) — —

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CL

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2022.

Exhibit 10.1 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the ?Company?), grants to the Optionee named below an option (the ?Option?) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the ?Plan?) and this nonqualified stock option agreement (the ?A

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three Months Ended September 30, 2022 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (4)% (21)% ?% ?% 17% (4)% (21)% Household (4) (14) ? ? 10 (4) (14) Lifestyle (3) (10) ? ? 7 (3) (10) International (1) (4) ? (9) 12 8 (4) Total (4)% (15)% ?% (2)% 13% (2)% (15)% (1) This represents the net impact on net sales growth/ (decrease) from pricing actions, mix and other factors.

Form of Performance Share Award Agreement under the Company's 2005 Stock Incentive Plan for awards made in 2022.

Exhibit 10.2 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the ?Company?), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the ?Plan?) and this performance share award agreement (the ?Agreement?), the following number of Perform

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Off-Cycle Grant).

Exhibit 10.4 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the ?Company?), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the ?Plan?) and this restricted stock unit award agreement (the ?Agreement?), the

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Annual Grant). for awards made in 2022.

Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the ?Company?), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the ?Plan?) and this restricted stock unit award agreement (the ?Agreement?), the

% Change(1)

PRESS RELEASE Clorox Reports Q1 Fiscal Year 2023 Results, Confirms Outlook OAKLAND, California, Nov.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by

Reconciliation of Economic Profit (Unaudited).

Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY22 FY21 FY20 Earnings before income taxes $ 607 $ 900 $ 1,185 Add back: Certain U.S. GAAP charges (2)(3) 61 357 2 Interest expense 106 99 99 Less: Saudi JV acquisition gain (4) ? (82) ? Earnings before income taxes, certain U.S. GAAP items and interest expense 774 1,274 1,286 Less: Income taxes

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except per share data) Management?s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company?s (the Company or Clorox) financial statements with a narrative from the perspective of ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________ ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2022 OR ☐ Transition report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2022 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Clorox de Mexico, S de RL de C.V.

Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Andover Properties, Inc.

% Change(1)

PRESS RELEASE Clorox Reports Q4 and FY22 Results, Provides FY23 Outlook and Announces Streamlined Operating Model OAKLAND, California, Aug.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three Months Ended June 30, 2022 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (5)% (18)% ?% ?% 13% (5)% (18)% Household 4 (4) ? ? 8 4 (4) Lifestyle 1 (3) ? ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1221 Broadway, Oakland, California 94612-1888 (Address of principal executive o

Exhibit 1.01 – Conflict Minerals Report of The Clorox Company

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2021 This Conflict Minerals Report (this “Report”) of The Clorox Company (the “Company” or “Clorox”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2021, to December 31, 2021. Rule 13p-1 require

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File Numb

Clorox Announces Appointment of Julia Denman and Stephanie Plaines to its Board of Directors

PRESS RELEASE Clorox Announces Appointment of Julia Denman and Stephanie Plaines to its Board of Directors OAKLAND, California, May 18 ? The Clorox Company (NYSE: CLX) today announced the appointment of Julia (Charter) Denman and Stephanie Plaines to its board of directors, bringing additional deep financial expertise and industry leadership experience.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 (May 12, 2022) THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commi

Indenture dated as of May 11, 2022, between the Company and U.S. Bank Trust Company, National Association, as trustee

Execution Version Exhibit 4.1 THE CLOROX COMPANY, Issuer U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of May 11, 2022 Senior Debt Securities THE CLOROX COMPANY TABLE OF CONTENTS ARTICLE 1 Definitions and Other Provisions of General Application 5 Section 101. Definitions 5 Section 102. Compliance Certificates and Opinions 12 Section 103. Form of Documents Delivered to T

Form of 4.400% Senior Note due 2029

EXHIBIT 4.3 [THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR THE SECURITIES IN CERTIFICATED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITORY TRUST COMPANY (THE ?DEPOSITARY?) TO A NOMINEE OF THE DEPO

Form of 4.600% Senior Note due 2032

EXHIBIT 4.4 [THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR THE SECURITIES IN CERTIFICATED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITORY TRUST COMPANY (THE ?DEPOSITARY?) TO A NOMINEE OF THE DEPO

Underwriting Agreement dated as of May 5, 2022

Exhibit 1.1 Execution Version The Clorox Company $500,000,000 4.400% Senior Notes due 2029 $600,000,000 4.600% Senior Notes due 2032 Underwriting Agreement May 5, 2022 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC MUFG Securities Americas Inc. RBC Capital Markets, LLC Wells Fargo Securities, LLC As representatives of the several Underwriters named in Schedule I hereto, c/o J.P. Morgan Securi

Company Order establishing the terms of the Securities

EXHIBIT 4.2 THE CLOROX COMPANY COMPANY ORDER Pursuant to the authorization of the Board of Directors of The Clorox Company (the ?Company?) in resolutions duly adopted by the Board of Directors of the Company by unanimous written consent on April 29, 2022 (the ?Resolutions?), the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of t

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 (May 5, 2022) THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commis

Calculation of Filing Fee Table (Form Type) THE CLOROX COMPANY (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Prop

EX-FILING FEES 2 d229814dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table 424(b)(2) (Form Type) THE CLOROX COMPANY (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price F

$1,100,000,000 4.400% Senior Notes due 2029 4.600% Senior Notes due 2032

Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-264693 PROSPECTUS SUPPLEMENT (to Prospectus dated May 5, 2022) $1,100,000,000 4.400% Senior Notes due 2029 4.600% Senior Notes due 2032 We are offering $500,000,000 aggregate principal amount of 4.400% senior notes due 2029 (the ?2029 notes?) and $600,000,000 aggregate principal amount of 4.600% senior notes due 2032 (the ?203

As filed with the Securities and Exchange Commission on May 5, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 5, 2022 Registration No.

Filing Fee Exhibit

EX-FILING FEES 6 d352524dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table FORM S-3 (Form Type) THE CLOROX COMPANY (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fe

Subject to Completion, dated May 5, 2022

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264693 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitt

Form of Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee

Exhibit 4.1 THE CLOROX COMPANY, Issuer U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of , Senior Debt Securities THE CLOROX COMPANY TABLE OF CONTENTS ARTICLE 1 Definitions and Other Provisions of General Application 6 Section 101. Definitions 6 Section 102. Compliance Certificates and Opinions 13 Section 103. Form of Documents Delivered to Trustee 13 Section 104. Acts o

Statement of Eligibility on Form T-1 of U.S. Bank Trust Company, National Association, to act as trustee under the Indenture

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

THE CLOROX COMPANY $500,000,000 4.400% SENIOR NOTES DUE 2029 $600,000,000 4.600% SENIOR NOTES DUE 2032 Pricing Term Sheet Issuer: The Clorox Company Ratings (Moody’s / S&P): Baa1 / BBB+ The securities ratings are made by the rating agencies and not t

Filed Pursuant to Rule 433 Registration Statement No. 333-264693 May 5, 2022 THE CLOROX COMPANY $500,000,000 4.400% SENIOR NOTES DUE 2029 $600,000,000 4.600% SENIOR NOTES DUE 2032 Pricing Term Sheet Issuer: The Clorox Company Ratings (Moody’s / S&P): Baa1 / BBB+ The securities ratings are made by the rating agencies and not the issuer or underwriters and a securities rating is not a recommendation

Reported Net Sales Growth/ (Decrease)

The Clorox Company Three Months Ended March 31, 2022 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (3)% 1% ?% ?% (4)% (3)% 1% Household 6 2 ? ? 4 6 2 Lifestyle 4 6 ? ? (2) 4 6 I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLOROX

% Change(1)

PRESS RELEASE Clorox Reports Q3 Fiscal Year 2022 Results, Updates Outlook OAKLAND, California, May 2, 2022 ? The Clorox Company (NYSE: CLX) today reported results for the third quarter of fiscal year 2022, which ended March 31, 2022.

May 2, 2022

CORRESP 1 filename1.htm May 2, 2022 Via EDGAR Ms. Nudrat Salik Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SEC Comment Letter dated April 20, 2022 The Clorox Company Form 10-K for the Fiscal Year Ended June 30, 2021 Form 10-Q for the Period Ended December 31, 2021 Form 8-K Filed February 3, 2

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Empl

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File Nu

Clorox Signs Second 12-year Renewable Energy Agreement, Continuing Its Commitment to 100% Renewable Electricity for Its U.S. and Canada Operations

PRESS RELEASE Clorox Signs Second 12-year Renewable Energy Agreement, Continuing Its Commitment to 100% Renewable Electricity for Its U.

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Credit Agreement, dated as of March 25, 2022, among The Clorox Company, the lenders listed therein, JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as Administrative Agents, and JPMorgan Chase Bank, N.A., as Servicing Ag

Exhibit 10.1 $1,200,000,000 CREDIT AGREEMENT dated as of March 25, 2022 among The Clorox Company, The Banks Listed Herein, JPMorgan Chase Bank, N.A., Citibank, N.A. and Wells Fargo Bank, National Association, as Administrative Agents, JPMorgan Chase Bank, N.A., as Servicing Agent, MUFG Bank, Ltd., Royal Bank of Canada and U.S. Bank National Association as Documentation Agents, JPMorgan Chase Bank,

Six month period ended

March 16, 2022 Via EDGAR Ms. Nudrat Salik Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SEC Comment Letter dated February 25, 2022 The Clorox Company Form 10-K for the Fiscal Year Ended June 30, 2021 Form 10-Q for the Period Ended December 31, 2021 Form 8-K Filed February 3, 2022 File No. 001-0

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-07151 (Commission File Number) 31

March 1, 2022

March 1, 2022 Ms. Nudrat Salik Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SEC Comment Letter dated February 25, 2022 The Clorox Company Form 10-K for the Fiscal Year Ended June 30, 2021 Form 10-Q for the Period Ended December 31, 2021 Form 8-K Filed February 3, 2022 File No. 001-07151 Dear M

CLX / Clorox Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Clorox Co. Title of Class of Securities: Common Stock CUSIP Number: 189054109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13

% Change(1)

EX-99.1 2 ex991-pressreleasedatedfeb.htm EX-99.1 PRESS RELEASE Clorox Reports Q2 Fiscal Year 2022 Results, Updates Outlook OAKLAND, California, Feb. 3, 2022 — The Clorox Company (NYSE: CLX) today reported results for the second quarter of fiscal year 2022, which ended on Dec. 31, 2021. Second-Quarter Fiscal Year 2022 Summary Following is a summary of key second-quarter results. All comparisons are

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Three Months Ended December 31, 2021 Percentage change versus the year-ago period

The Clorox Company Three Months Ended December 31, 2021 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (21)% (18)% ?% ?% (3)% (21)% (18)% Household 3 (2) ? ? 5 3 (2) Lifestyle 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLO

Third Amended and Restated Executive Change in Control Severance Plan, effective November 17, 2021

THE CLOROX COMPANY THIRD AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN EFFECTIVE NOVEMBER 17, 2021 THIS EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN (the ?Plan?) was originally adopted and approved by the Management Development and Compensation Committee (the ?Committee?) of the Board of Directors (?Board?) of THE CLOROX COMPANY, a Delaware corporation (the ?Company?), on December 17, 2010 and became effective immediately upon such adoption.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S

Severance Plan for Clorox Executive Committee Members, fourth amended and restated effective November 17, 2021.

EX-10.3 3 clorox3984651-ex103.htm SEVERANCE PLAN FOR CLOROX EXECUTIVE COMMITTEE MEMBERS Severance Plan for Clorox Executive Committee Members Fourth Amended and Restated Effective as of November 17, 2021 The Severance Plan for Clorox Executive Committee Members (the “Plan”) provides benefits in certain instances to Participants who are employed by The Clorox Company, a Delaware corporation (“Cloro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CL

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended September 30, 2021

EX-99.2 3 clorox3976951-ex992.htm SUPPLEMENTAL INFORMATION REGARDING FINANCIAL RESULTS The Clorox Company Three Months Ended September 30, 2021 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health

Clorox Reports Q1 Fiscal Year 2022 Results, Confirms Outlook

PRESS RELEASE Clorox Reports Q1 Fiscal Year 2022 Results, Confirms Outlook OAKLAND, California, Nov.

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2021.

Exhibit 10.4 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the ?Company?), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the ?Plan?) and this performance share award agreement (the ?Agreement?), the following number of Perform

The Clorox Company Annual Incentive Plan, amended and restated as of September 21, 2021.

Exhibit 10.1 THE CLOROX COMPANY ANNUAL INCENTIVE PLAN As Amended and Restated Effective as of September 21, 2021 1. Purpose. The purpose of The Clorox Company Annual Incentive Plan (the ?Plan?) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a Delaware corporation (the ?Company?) and

Amendment No. 1 to Third Amended and Restated 2005 Stock Incentive Plan of The Clorox Company, effective as of September

Exhibit 10.2 AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN OF THE CLOROX COMPANY This AMENDMENT NO. 1 to the Third Amended and Restated 2005 Stock Incentive Plan (the “Plan”) of The Clorox Company (the “Company”) was approved by the Management Development and Compensation Committee of the Board of Directors of the Company, effective as of September 21, 2021. Pursuant to t

Form of Restricted Stock Unit Award Agreement under the Company

EX-10.5 6 clxq1fy22exhibit105.htm EX-10.5 Exhibit 10.5 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock u

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan.

EX-10.3 4 clxq1fy22exhibit103.htm EX-10.3 Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this n

Form of Restricted Stock Unit Award Agreement under the Company

EX-10.6 7 clxq1fy22exhibit106.htm EX-10.6 Exhibit 10.6 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 clorox3957551-defa14a.htm DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statemen

The Clorox Company 2005 Stock Incentive Plan, amended and restated as of November 17, 2021

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by

Name of Company

EX-21 2 fy21clxex21.htm EX-21 Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Andover Properties, Inc. Delaware Iodine Holdings, Inc. Connecticut Brita Canada Corporation Nova Scotia Brita Canada Holdings Corporation Nova Scotia Brita GP Ontario Brita LP Ontario Brita Manufacturing Company Delaware The Brita Pro

Reconciliation of Economic Profit (Unaudited).

EX-99.2 8 fy21clxex99210k.htm EX-99.2 Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY21 FY20 FY19 Earnings before income taxes $ 900 $ 1,185 $ 1,024 Add back: Non-cash U.S. GAAP charges (2) 357 2 2 Interest expense 99 99 97 Less: Saudi JV acquisition gain (3) (82) — — Earnings before income taxes, non-cash U.S. GAAP items and interest expens

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except per share data) Management?s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company?s (the Company or Clorox) financial statements with a narrative from the perspective of ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2021 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Clorox Reports Fourth Quarter and Fiscal Year 2021 Results, Provides Fiscal Year 2022 Outlook

EX-99.1 2 clorox3938801-ex991.htm EARNINGS PRESS RELEASE Press Release Clorox Reports Fourth Quarter and Fiscal Year 2021 Results, Provides Fiscal Year 2022 Outlook OAKLAND, Calif., Aug. 3, 2021 – The Clorox Company (NYSE: CLX) reported a 9% sales decrease and a 68% decrease in diluted net earnings per share (diluted EPS) for its fourth quarter, which ended June 30, 2021. For fiscal year 2021, the

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended June 30, 2021

EX-99.2 3 clorox3938801-ex992.htm SUPPLEMENTAL FINANCIAL INFORMATION The Clorox Company Three Months Ended June 30, 2021 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Net Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (17)%

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) _______________

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 1221 Broadway, Oakland, California 94612-1888 (Address of principal executive o

Exhibit 1.01 – Conflict Minerals Report of The Clorox Company

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2020 This Conflict Minerals Report (this ?Report?) of The Clorox Company (the ?Company? or ?Clorox?) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (?Rule 13p-1?), for the reporting period from January 1, 2020, to December 31, 2020. Rule 13p-1 require

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLOROX

The Clorox Company Annual Incentive Plan, amended and restated as of February 9, 2021.

EX-10.1 2 clxq3fy21exhibit101.htm EX-10.1 Exhibit 10.1 THE CLOROX COMPANY ANNUAL INCENTIVE PLAN As Amended and Restated Effective as of February 9, 2021 1.Purpose. The purpose of The Clorox Company Annual Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a De

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2021.

EX-10.5 6 clxq3fy21exhibit105.htm EX-10.5 Exhibit 10.5 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Ag

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Off-Cycle Grant).

EX-10.7 8 clxq3fy21exhibit107.htm EX-10.7 Exhibit 10.7 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock u

Severance Plan for Clorox Executive Committee Members, third amended and restated effective February 9, 2021.

EX-10.8 9 clxq3fy21exhibit108.htm EX-10.8 Exhibit 10.8 Severance Plan for Clorox Executive Committee Members Third Amended and Restated Effective as of February 9, 2021 The Severance Plan for Clorox Executive Committee Members (the “Plan”) provides benefits in certain instances to Participants who are employed by The Clorox Company, a Delaware corporation (“Clorox”) or an Affiliate (as defined bel

Clorox Reports Q3 Fiscal Year 2021 Results, Updates Fiscal Year Outlook

EX-99.1 2 clorox3903641-ex991.htm PRESS RELEASE DATED APRIL 30, 2021 OF THE CLOROX COMPANY PRESS RELEASE Clorox Reports Q3 Fiscal Year 2021 Results, Updates Fiscal Year Outlook OAKLAND, Calif., April 30, 2021 — In its fiscal third quarter ending March 31, 2021, The Clorox Company (NYSE: CLX) reported flat sales and diluted net loss per share (diluted EPS) of 49 cents, a 126% decrease compared to t

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended March 31, 2021

The Clorox Company Three Months Ended March 31, 2021 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Net Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness (8)% (11)% ?% ?% 3% (8)% (11)% Household 6 4 ? ? 2 6 4 Lifestyle ? (1) ? ?

The Clorox Company 2005 Stock Incentive Plan, First Amendment and Restatement as of November 14, 2012; Second Amendment and Restatement as of September 22, 2020; Third Amendment and Restatement as of February 9, 2021.

EX-10.3 4 clxq3fy21exhibit103.htm EX-10.3 Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN Effective as of November 16, 2005 First Amendment and Restatement as of November 14, 2012 Second Amendment and Restatement as of September 22, 2020 Third Amendment and Restatement as of February 9, 2021 1. Establishment, Objectives and Duration. (a) Establishment of the Plan. The Clorox Company, a D

The Clorox Company Executive Incentive Compensation Plan, amended and restated as of February 9, 2021.

EX-10.2 3 clxq3fy21exhibit102.htm EX-10.2 Exhibit 10.2 THE CLOROX COMPANY EXECUTIVE INCENTIVE COMPENSATION PLAN As Amended and Restated Effective as of February 9, 2021 1.Establishment, Objectives, Duration. The Clorox Company, a Delaware corporation (hereinafter referred to as the “Company”) hereby establishes a short-term incentive compensation plan to be known as the “The Clorox Company Executi

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan.

EX-10.4 5 clxq3fy21exhibit104.htm EX-10.4 Exhibit 10.4 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this n

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Annual Grant).

EX-10.6 7 clxq3fy21exhibit106.htm EX-10.6 Exhibit 10.6 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock u

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Em

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S.

SC 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING CLOROX CO/THE (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 189054109 (CUSIP NUMBER) 12/31/2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)*

SC 13G/A 1 tv0558-cloroxco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Clorox Co. Title of Class of Securities: Common Stock CUSIP Number: 189054109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursua

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CLO

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended December 31, 2020

The Clorox Company Three Months Ended December 31, 2020 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Net Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness 42% 36% —% —% 6% 42% 36% Household 20 18 — — 2 20 18 Lifestyle 9 8 — —

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Clorox Reports Q2 Fiscal Year 2021 Results, Updates Fiscal Year Outlook

EX-99.1 2 clorox3865961-ex991.htm PRESS RELEASE DATED FEBRUARY 4, 2021 OF THE CLOROX COMPANY PRESS RELEASE Clorox Reports Q2 Fiscal Year 2021 Results, Updates Fiscal Year Outlook OAKLAND, Calif., Feb. 4, 2021 — The Clorox Company (NYSE:CLX) reported sales growth of 27% and an increase in diluted net earnings per share (diluted EPS) of 39% for its second quarter of fiscal year 2021, which ended Dec

Acknowledgement Letter to the Amended and Restated Joint Venture Agreement, dated as of October 7, 2020, between The Glad Products Company and certain affiliates and The Procter & Gamble Company and certain affiliates.

Exhibit 10.1 ACKNOWLEDGEMENT LETTER TO THE AMENDED AND RESTATED JOINT VENTURE AGREEMENT DATED AS OF JANUARY 31, 2003 This Acknowledgement Letter to the Amended and Restated Joint Venture Agreement License Agreement (“Acknowledgment Letter”) is entered into as of the seventh day of October, 2020 between and among The Glad Products Company, a Delaware corporation, Glad Manufacturing Company, a Delaw

Clorox Announces Changes to Board of Directors

EX-99.1 2 clorox3863281-ex991.htm PRESS RELEASE DATED JANUARY 28, 2021, OF THE CLOROX COMPANY PRESS RELEASE Clorox Announces Changes to Board of Directors Executive Chair Benno Dorer to Step Down; Matthew Shattock Appointed to Independent Chair; Esther Lee Appointed Chair of NGCRC; Lead Independent Director Pamela Thomas-Graham to Step Down from the Board in November 2021 OAKLAND, Calif., Jan. 28,

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Longtime Finance Leader and Life Sciences Executive Paul Parker Elected to Clorox Board

EX-99.1 2 clorox3831591-ex991.htm PRESS RELEASE PRESS RELEASE Longtime Finance Leader and Life Sciences Executive Paul Parker Elected to Clorox Board OAKLAND, Calif., Nov. 18, 2020 – The Clorox Company (NYSE:CLX) announced today that Paul Parker was formally elected to serve on its board of directors. Currently a corporate officer and senior vice president of strategy and corporate development for

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended September 30, 2020

The Clorox Company Three Months Ended September 30, 2020 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Net Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health and Wellness 28% 26% —% —% 2% 28% 26% Household 39 25 — — 14 39 25 Lifestyle 17 17 — — — 17 17 International 18 17 9 (8) 8 17 9 Total 27% 23% 1% (1%) 5% 27% 22% (1) This represents the net impact on net sales growth/ (decrease) from pricing action, mix and other factors.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File

Clorox Reports Q1 Fiscal Year 2021 Results, Updates Fiscal Year Outlook

EX-99.1 2 clorox3824331-ex991.htm PRESS RELEASE DATED NOVEMBER 2, 2020 OF THE CLOROX COMPANY PRESS RELEASE Clorox Reports Q1 Fiscal Year 2021 Results, Updates Fiscal Year Outlook OAKLAND, Calif., Nov. 2, 2020 — The Clorox Company (NYSE:CLX) reported sales growth of 27% and an increase in diluted net earnings per share (diluted EPS) of 103% for its first quarter of fiscal year 2021, which ended Sep

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2020.

Exhibit 10.4 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT NOTICE OF PERFORMANCE SHARE GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Agreement”), the following number of Perform

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan.

Exhibit 10.5 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT NOTICE OF STOCK OPTION GRANT The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this nonqualified stock option agreement (the “A

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Off-Cycle Grant).

Exhibit 10.3 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-07151 THE CL

The Clorox Company 2005 Stock Incentive Plan, First Amendment and Restatement as of November 14, 2012; Second Amendment and Restatement as of September 22, 2020.

Exhibit 10.1 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN Effective as of November 16, 2005 First Amendment and Restatement as of November 14, 2012 Second Amendment and Restatement as of September 22, 2020 1. Establishment, Objectives and Duration. (a) Establishment of the Plan. The Clorox Company, a Delaware corporation (hereinafter referred to as the “Company”), hereby establishes an incentive c

Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Annual Grant) for awards made in 2020.

Exhibit 10.2 THE CLOROX COMPANY 2005 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (US Employees) SUMMARY OF RESTRICTED STOCK UNIT AWARD The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the

- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

DEFA14A 1 clx3823891-defa14a.htm DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [

- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- DEFINITIVE PROXY STATEMENT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by

- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- PRELIMINARY PROXY STATEMENT

PRE 14A 1 clorox3806961-pre14a.htm PRELIMINARY PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [

Name of Company

Exhibit 21 Name of Company Jurisdiction of Incorporation 6570 Donlon Group, LLC Delaware A & M Products Manufacturing Company Delaware Andover Properties, Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The Clorox Company (Dollars in millions, except share and per share data) Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspec

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2020 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to. Commission file number: 1-07151 THE CLOROX C

Reconciliation of Economic Profit (Unaudited).

Exhibit 99.2 THE CLOROX COMPANY RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1) Dollars in millions FY20 FY19 FY18 Earnings before income taxes $ 1,185 $ 1,024 $ 1,054 Add back: Non-cash U.S. GAAP restructuring and intangible asset impairment charges 2 2 2 Interest expense 99 97 85 Earnings before income taxes, non-cash U.S. GAAP restructuring and intangible asset impairment charges, and interes

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File N

Supplemental Schedule of recast Net Sales and Earnings (Losses) before Income Taxes of the Company’s reportable segments for the fiscal years 2020, 2019 and 2018 Fiscal Year 2020 Net sales (2) ($ millions) Q1 Q2 Q3 Q4 Fiscal Year Segment As Reported

The Clorox Company Supplemental Schedule of recast Net Sales and Earnings (Losses) before Income Taxes of the Company’s reportable segments for the fiscal years 2020, 2019 and 2018 Fiscal Year 2020 Net sales (2) ($ millions) Q1 Q2 Q3 Q4 Fiscal Year Segment As Reported As Recast As Reported As Recast As Reported As Recast As Reported As Reported Health and Wellness (Formerly Cleaning)(1) $ 562 $ 63

Supplemental Unaudited Condensed Information – Cash Flow For the quarter ended June 30, 2020

EX-99.3 4 clorox3790291-ex993.htm SUPPLEMENTAL INFORMATION REGARDING FINANCIAL RESULTS The Clorox Company Three Months Ended June 30, 2020 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth/ (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price Mix and Other (1) Organic Net Sales Growth/ (Decrease) (Non-GAAP) (2) Organic Volume (3) Health a

Clorox Reports Q4 and Fiscal Year 2020 Results, Provides Fiscal Year 2021 Outlook

EX-99.1 2 clorox3790291-ex991.htm PRESS RELEASE DATED AUGUST 3, 2020 OF THE CLOROX COMPANY PRESS RELEASE Clorox Reports Q4 and Fiscal Year 2020 Results, Provides Fiscal Year 2021 Outlook OAKLAND, Calif., Aug. 3, 2020 – The Clorox Company (NYSE:CLX) reported a 22% sales increase, including double-digit growth across all reportable segments, and a 28% increase in diluted net earnings per share (dilu

Linda Rendle Promoted to Clorox CEO; Benno Dorer to Continue as Chair of the Board

Linda Rendle Promoted to Clorox CEO; Benno Dorer to Continue as Chair of the Board OAKLAND, Calif.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File Num

- ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

- ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-07151 A.

- SPECIALIZED DISCLOSURE REPORT

SD 1 clorox3763051-sd.htm SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 1221 Broadway, Oakland,

The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2019

Exhibit 1.01 The Clorox Company Conflict Minerals Report for the Year Ended December 31, 2019 This Conflict Minerals Report (this “Report”) of The Clorox Company (the “Company” or “Clorox”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2019, to December 31, 2019. Rule 13p-1 require

Eighth Supplemental Indenture, dated as of May 8, 2020, between the Company and Wells Fargo Bank, National Association, as trustee.

EX-4.1 3 d929558dex41.htm EX-4.1 Exhibit 4.1 THE CLOROX COMPANY EIGHTH SUPPLEMENTAL INDENTURE Dated as of May 8, 2020 with WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee To INDENTURE Dated as of October 9, 2007 with THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee Senior Debt Securities 1.800% Senior Notes due 2030 EIGHTH SUPPLEMENTAL INDENTURE EIGHTH SUPPLEMENTAL INDENTURE (this “S

Underwriting Agreement, dated as of May 5, 2020

EX-1.1 Exhibit 1.1 The Clorox Company $500,000,000 1.800% Senior Notes due 2030 Underwriting Agreement May 5, 2020 Citigroup Global Markets Inc. Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Wells Fargo Securities, LLC As representatives of the several Underwriters named in Schedule I hereto, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) Delaware 1-07151 31-0595760 (State or other jurisdiction of incorporation) (Commission File Numbe

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Maximum offering price per unit Maximum aggregate offering price Amount of Registration Fee (1) 1.800% Senior Notes due 2030 $500,000,000 99.10

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-224699 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Maximum offering price per unit Maximum aggregate offering price Amount of Registration Fee (1) 1.800% Senior Notes due 2030 $500,000,000 99.109% $495,545,000 $64,321.74 (1) Calculated in accordance with Rule